< Back to Press

ASCENSIA ANNOUNCES ART AND PHOTO COMPETITION FOR WORLD DIABETES DAY 2023

Parsippany, United States

This year’s competition aims to raise awareness of diabetes and highlight the real lives of people living with the condition across the world

Ascensia Diabetes Care, a global diabetes care company, owner of the CONTOUR^® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense^® Continuous Glucose Monitoring (CGM) Systems, has opened submissions for its successful art and photo competition in support of World Diabetes Day 2023. This year, Ascensia’s global competition is themed around diabetes in real life, aiming to capture the genuine challenges, successes and day-to-day realities of people living with diabetes.

1 in 10 adults is living with diabetes, while an estimated 783 million people will have the disease in 2045. This means that it is more important than ever to raise awareness of diabetes and what real life looks like for those who live with the condition. Ascensia’s ‘This is Diabetes, This is Real’ competition seeks to gather a collection of original artworks submitted by people across the world, with each one telling a personal story about their journey with diabetes.

You can submit illustrations, photographs and digital designs at www.thisisdiabetes.com until October 31, with the winners of the competition announced on World Diabetes Day, a global initiative of the International Diabetes Federation (IDF) taking place each year on November 14.

Rob Schumm, CEO of Ascensia Diabetes Care, commented: “World Diabetes Day is an important day to us at Ascensia and we are proud to support IDF on this initiative for the eighth consecutive year.

“This will be the third year that we have run our art and photo competition and I cannot wait to see everyone’s submissions,” he added. “Each year I am completely awed by the artwork submitted and the powerful stories behind each piece. For our 2023 ‘This is Diabetes, This is Real’ competition we are encouraging people of all ages and abilities to submit a piece that tells a story about what diabetes in real life means to them. Whether you draw, paint, or snap, we want you to capture diabetes without the filter, from your daily struggles to your proudest moments. Let’s get creative and show the world diabetes in real life.”

Competition winners will be able to donate €6,000, €3,000 and €1,000 for first, second and third place respectively to a diabetes charity of their choice. The judging panel, including members of the diabetes online community, professional artists, Ascensia employees and an Eversense brand ambassador, will be looking for creativity, storytelling, and connection to this year’s theme.

This year’s competition looks to build upon the success of 2021 and 2022’s ‘This is Diabetes’ campaigns. Last year Ascensia received over 350 entries from around the globe and donated €10,000 to nominated diabetes charities across 4 different continents. For inspiration, you can see previous winners by visiting the Ascensia website, the 2021 campaign page here, or the 2022 campaign page here.

Ascensia Diabetes Care is a PHC Holdings Corporation (TSE: 6523) company.

END

¹According to the IDF Diabetes Atlas 10th edition, published 2021

Notes for Editors

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.

We are home to the world-renowned CONTOUR^® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense^® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia is a member of PHC Group. Ascensia products are sold in more than 100 countries. Ascensia has around 1,300 employees and operations in 31 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com

About PHC Holdings Corporation

PHC Holdings Corporation (TSE 6523), or PHC Group, is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia, and LSI Medience Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2021 were JPY 340 billion with global distribution of products and services in more than 125 countries. www.phchd.com

About Eversense

The Eversense^® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://www.ascensiadiabetes.com/eversense/safety-info/.

For more media enquiries, please contact:

Tim Stamper, Tim.Stamper@FTIConsulting.com